Charles River Laboratories (CRL) is facing headwind issues in its research and model services, or RMS segment, which contributes approximately 61% of the total net sales of the company and posted $182.5 million revenue in the first quarter of 2013. The total revenue declined by 2.1% compared to the previous year, but it grew by about 6% compared to its previous quarter. Most of its biopharmaceutical clients set their budgets and spending priorities for the coming year in the last quarter of the year. And hence, the last quarters never generate higher revenue. As a result, the quarterly growth, even though it is impressive, doesn't look promising to me.
Charles River acquired Accugenix and Vital...
Only subscribers can access this article, which is part of the PRO research library covering 3,618 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: